Stelara (Ustekinumab)

This is a medicine used to treat plaque psoriasis. It's an injection that helps reduce the inflammation causing the skin patches. It works by blocking certain immune system proteins involved in the disease.

Brand names:Stelara
Medication

What people taking Stelara (Ustekinumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Stelara (Ustekinumab) for Psoriasis?

NameHow it went

About Stelara (Ustekinumab)

What It's For

Ustekinumab, best known by the brand name Stelara, is a prescription biologic medicine for four long-term inflammatory conditions. It treats moderate to severe plaque psoriasis in adults and children 6 and older who need more than creams, meaning they are candidates for light therapy or whole-body treatment. It also treats active psoriatic arthritis (joint inflammation linked to psoriasis) from age 6, and moderately to severely active Crohn's disease and ulcerative colitis, the two main forms of inflammatory bowel disease, from age 2. A biologic is a medicine made from living cells, usually a large protein such as an antibody. Since 2023 the US Food and Drug Administration (FDA) has approved several biosimilars of Stelara, including Wezlana, Selarsdi and Yesintek. A biosimilar is a closely matched version of the original biologic with no clinically meaningful differences in safety or effectiveness, and it is often less expensive. Your insurer or pharmacy may supply one of these in place of Stelara.

How It Works

In these conditions, the immune system keeps sending inflammatory signals when there is no infection to fight. Two of those signals are interleukin-12 and interleukin-23 (IL-12 and IL-23), messenger proteins that activate certain immune cells and help sustain the inflammation seen in psoriasis plaques, inflamed joints and the lining of the gut. Ustekinumab is a monoclonal antibody, a lab-made immune protein designed to latch onto one specific target. It binds a piece that IL-12 and IL-23 share, which stops both from switching on their receptors. With that signaling turned down, inflammation gradually settles, so skin plaques thin and clear, joints become less swollen and the bowel lining can heal. Because it quiets part of the immune system, it also makes some infections harder to fight off.

Dosage & Administration

How ustekinumab is given depends on the condition. For psoriasis and psoriatic arthritis, it is an injection under the skin: one dose to start, a second four weeks later, and then one every 12 weeks. For Crohn's disease and ulcerative colitis, treatment begins with a single intravenous (IV) infusion into a vein at an infusion center or clinic, followed by an injection under the skin eight weeks later and then every eight weeks. Doses are set by body weight, so a heavier person or a child may receive a different amount. After training, many adults inject themselves at home or have a caregiver do it, using the thigh, abdomen, upper arm or buttocks and changing the spot each time. For children, a healthcare provider usually gives the injection. The needle cover on the Stelara prefilled syringe contains latex, which matters for anyone with a latex allergy. If a dose is missed, ask the care team how to get back on track.

Side Effects

Most people have few noticeable side effects. The most common are cold-like symptoms such as a sore throat or stuffy nose, other upper respiratory infections, headache and tiredness. Some people get redness or soreness where they inject. People using it for inflammatory bowel disease have also reported sinus infections, urinary tract infections and vaginal yeast infections. The more important risk is infection. Contact the care team promptly about fever, chills, a cough that will not go away, painful red or warm skin, burning when urinating or other signs of infection, since treatment may need to be paused until the infection clears. Rarely, ustekinumab causes inflammation in the lungs that is not an infection, with a new cough or shortness of breath, which should also be reported promptly. Serious allergic reactions are uncommon but can happen, including during the first IV infusion. Swelling of the face, lips or throat, or trouble breathing, needs emergency care. Very rarely, a brain condition called posterior reversible encephalopathy syndrome (PRES) has been reported; a seizure or sudden confusion with a severe headache or vision changes also needs emergency care.

Interactions & Warnings

Before starting, you will be tested for tuberculosis (TB). If the test shows a dormant TB infection, it is treated first, because suppressing the immune system can allow TB to become active. Anyone with an active infection, or a history of frequent or chronic infections, should discuss this before beginning. Ustekinumab should not be used by someone who has had a serious allergic reaction to any ustekinumab product. Vaccines are best brought up to date before treatment starts. Live vaccines (those made from weakened live germs) should be avoided during treatment, and the Bacille Calmette-Guérin (BCG) vaccine against tuberculosis should be avoided for a year before, during and a year after treatment. Non-live vaccines can still be given, though they may work less well. Household members getting a live vaccine is also worth mentioning to the care team. Ustekinumab may slightly increase the risk of some cancers, particularly non-melanoma skin cancers. Regular skin checks are worthwhile, especially for people over 60, those who have taken immune-suppressing medicines for a long time and those who have had PUVA (a psoriasis light treatment combined with a sensitizing medicine). People receiving allergy shots should tell their allergist, because ustekinumab may make a reaction to a shot more likely. Starting or stopping it can also change how the body handles a few medicines with a narrow safe range that are processed by the liver, so their effect or blood levels may need checking. For pregnancy, studies so far have not found a higher risk of birth defects or miscarriage, though the data are limited. The medicine crosses the placenta late in pregnancy, so tell the baby's doctor about the exposure. Anyone pregnant, planning pregnancy or breastfeeding should weigh the options with the care team.

What to Expect

Ustekinumab works gradually. In psoriasis trials, about two-thirds to three-quarters of adults had their psoriasis at least 75% improved by week 12, compared with a few percent on placebo. In Crohn's disease and ulcerative colitis, the team usually judges the response over the first several months after the infusion, using symptoms and sometimes blood tests, stool tests or a colonoscopy. Not everyone responds, and some people lose response over time, in which case dose timing may be adjusted or another treatment chosen. It is meant as long-term maintenance treatment. It controls inflammation rather than curing the underlying condition, so when it works, staying on schedule is what keeps symptoms in check. Some people with inflammatory bowel disease continue other medicines alongside it, such as immunomodulators or steroids. Expect regular follow-up visits, skin checks and attention to infections, and let every clinician, including surgeons and dentists, know you take it.

Questions to Ask Your Doctor

  1. 1.Why is ustekinumab a good fit for my condition compared with other biologics or pills?
  2. 2.Will I receive Stelara or a biosimilar, and does it matter which one?
  3. 3.How and when will we decide whether it is working, and what happens if it is not?
  4. 4.Which vaccines should I get before starting, and which should I avoid?
  5. 5.What signs of infection should make me call you, and should I skip a dose when I am sick?

Last reviewed • Oct 2026

Educational content, not medical advice.